Vigil Neuroscience reported positive Phase 1 trial results for VG-3927 and plans a Phase 2 trial in Q3 2025. Vigil Neuroscience, Inc. announced promising outcomes from a Phase 1 clinical trial of ...
HONOLULU (HawaiiNewsNow) - State Attorney General Anne Lopez on Wednesday released what’s been described as the first phase of an exhaustive probe into the catastrophic Maui wildfires, offering a ...
On March 14, 2025, the Leadership Oversight Advisory Group and the Co-Leads from each task force met to debrief and begin the next steps in identifying strategic priorities for short-term ...
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative ...